Mabtech involved in the development of a promising Alzheimer’s drug

As immunologists and using antibodies as our main tool, we were extremely happy to learn the result of the recent Eisai/BioArctic phase 3 clinical trial where treatment with the antibody lecanemab was shown to significantly delay the progression of Alzheimer’s disease. We also feel proud that the original murine monoclonal antibody, now used in a humanized form, was once developed as part of a collaboration between BioArctic, Uppsala University, and Mabtech.

With the antibody selectively recognizing the protofibrillar form of the Aβ protein, the study provides further support for the importance of protofibrils as the causative agent.

We hope that this new therapy will soon be in clinical use and that it can offer help to the many people who are subjected to this growing and devastating disease.

Read more in Bioarctic’s press release